Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-Pinene is a naturally occurring bicyclic monoterpene and a structural isomer of alpha-pinene, found as a major constituent in conifers (turpentine), various essential oils, and cannabis. While not an approved pharmaceutical drug, it is a widely studied small molecule research compound known for its antimicrobial, anti-inflammatory, and potential anticancer biological activities. Its mechanism of action involves partial agonism of the CB1 and CB2 cannabinoid receptors, as well as inhibition of cyclooxygenase (COX) enzymes and acetylcholinesterase. Recent academic research has also identified its ability to relax airway smooth muscle and significantly potentiate the bronchodilatory effects of beta-2 adrenergic receptor agonists like isoproterenol, suggesting therapeutic potential for respiratory conditions such as asthma. Additionally, beta-pinene serves as a chemical scaffold for the synthesis of novel derivatives with enhanced activity against pathogens like MRSA and *Candida albicans*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-pinene.